Responses
Clinical/translational cancer immunotherapy
Original research
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
Compose a Response to This Article
Other responses
No responses have been published for this article.